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Adverse eventsAdverse effects of long-term usage of triclosan-containing toothpaste in humans are currently unknown. We
assessed the effect of long-term use of 0.3% triclosan-toothpaste on serious adverse events (SAEs) in patients
with cardiovascular disease (CVD). 438 patients with a history of stable CVDwere entered into the 5-year longi-
tudinal Cardiovascular and Periodontal Study at Prince Charles Hospital, Brisbane, Australia and randomised into
test (triclosan) or placebo groups. There were no signiﬁcant differences in demographics or clinical features be-
tween the groups. Patientswere examined at baseline, and annually for 5-years. SAEswere classiﬁed according to
the System Organ Classes deﬁned by MedDRA (Medical Dictionary for Regulatory Activities). Results were
analysed using chi square and Kaplan Meier analysis. Overall, 232 patients (123 in the triclosan group; 109 in
the placebo group) experienced 569 SAEs (288 in the triclosan group and 281 in the placebo group). There
was no signiﬁcant difference between the groups in numbers of patients experiencing SAEs (p = 0.35) or speciﬁc
cardiovascular SAEs (p = 0.82), nor in time to the ﬁrst SAE or ﬁrst cardiovascular SAE, irrespective of gender, age
or BMI after adjusting formultiple comparisons (p N 0.05). The adjusted odds of experiencing an SAEwere estimated
to increase by 2.7% for each year of age (p= 0.02) and the adjusted odds of experiencing a cardiovascular SAEwere
estimated to increase by 5.1% for each unit increase in BMI (p = 0.02). Most cardiovascular events were related to
unstable angina ormyocardial infarcts, 21were associatedwith arrhythmia and41were vascular events such as aor-
tic aneurysm and cerebrovascular accident.Within the limitations of the present study the data suggest that the use
of triclosan-toothpaste may not be associated with any increase in SAEs in this CVD population. The long-term
impact of triclosan on hormone-related disease, such as cancer, in humans remains to be determined.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).ty ofQueensland, Prince Charles
lia.
), j.palmer@uq.edu.au
alcolm.west@uq.edu.au
ory.seymour@otago.ac.nz
. This is an open access article under1. Introduction
Triclosan (2′-hydroxy-2,4,4′-trichlorodiphenyl ether) is a broad
spectrum antibacterial, which has been used in personal care and
household products including toothpaste, for many years. Although it
is considered to have low toxicity in mammals (Bhargava and
Leonard, 1996), it has nevertheless been found in human plasma,
urine and breast milk (Allmyr et al., 2006a, 2006b, 2008; Calafat et al.,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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with the use of triclosan-containingproducts (Allmyr et al., 2008, 2009).
Because of its structural similarity to thyroid hormones, animal studies
have been carried out to investigate the effect of oral administration of
triclosan on the levels of serum thyroid hormones (Crofton et al.,
2007; Paul et al, 2010; Zorilla et al., 2009). While these studies showed
a dose dependent reduction in the levels of these hormones in rats,
there is no evidence for a similar effect in humans (Witorsch, 2014). In-
deed, Allmyr et al. (2009) showed that the use of a triclosan toothpaste
over 14 days had no effect on thyroid hormone levels, andwe have pre-
viously shown that continuous use of triclosan toothpaste over 4-years
had no detectable effect on thyroid function (Cullinan et al, 2012). Sim-
ilarly, studies looking at haematological or clinical/biochemical parame-
ters showed that the use of triclosan toothpaste for up to 4-years
resulted in no clinically relevant changes in these parameters (reviewed
in Rodricks et al., 2010).
While the usefulness of triclosan in household and personal care
products may be questionable, triclosan-containing toothpaste has
been shown to be effective in the control of plaque and gingivitisFig. 1. Consort(reviewed in Blinkhorn et al., 2009) and in slowing the progression of
periodontitis in susceptible people (Rosling et al., 1997; Ellwood et al.,
1998; Cullinan et al., 2003) and hence has a deﬁned therapeutic beneﬁt
which contributes signiﬁcantly to the maintenance of oral health. The
association between periodontitis and cardiovascular disease (CVD) is
now well established such that individuals with periodontitis are at
higher risk of having CVD than periodontally healthy patients
(Bahekar et al., 2007; Humphrey et al., 2008). It is less clear whether
those with CVD represent a susceptible population with regard to the
progression of periodontitis andwhether theymay beneﬁt from regular
use of triclosan toothpaste in slowing the progression of periodontitis.
However, patients with existing CVD represent an at-risk, or suscepti-
ble, group for secondary cardiovascular events and a recent study
in mice suggests that triclosanmayweaken cardiac muscle contractility
and thus could lead to adverse outcomes in humans with CVD,
particularly after prolonged exposure (Cherednichenkoa et al., 2012).
As yet there are no long-term studies investigating possible serious
cardiovascular effects of triclosan in humans. The present study,
therefore, investigated whether the use of triclosan toothpaste over 5-diagram.
Table 2a
Number of events in each patient group, and percentage of the total number of events in
each group that fell into each of the classes.
Triclosan
(n (%) of events)
Placebo
(n (%) of events)
Blood and lymphatic system disorders 2 (0.7) 6 (2.1)
Cardiac disorders 86 (29.9) 65 (23.1)
Ear and labyrinth disorders 0 1 (0.4)
Endocrine disorders 1 (0.3) 2 (0.7)
Gastrointestinal disorders 15 (5.2) 17 (6.0)
General disorders and administration
site conditions
56 (19.4) 62 (22.1)
Hepatobiliary disorders 6 (2.1) 4 (1.4)
Infections and infestations 10 (3.5) 9 (3.2)
Injury, poisoning and procedural
complications
3 (1.0) 3 (1.1)
Metabolism and nutrition disorders 8 (2.8) 4 (1.4)
Musculoskeletal and connective tissue
disorders
15 (5.2) 10 (3.6)
Neoplasms benign, malignant and
unspeciﬁed (incl cysts and polyps)
23 (8.0) 15 (5.3)
Nervous system disorders 5 (1.7) 1 (0.4)
Psychiatric disorders 1 (0.3) 0
Renal and urinary disorders 10 (3.5) 12 (4.3)
Reproductive system and breast
disorders
5 (1.7) 8 (2.8)
Respiratory, thoracic and mediastinal
disorders
18 (6.3) 22 (7.8)
Skin and subcutaneous tissue disorders 2 (0.7) 3 (1.1)
Social circumstances 0 3 (1.1)
Surgical and medical procedures 5 (1.7) 10 (3.6)
Vascular disorders 17 (5.9) 24 (8.5)
Total 288 (100.0) 281 (100.0)
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disease.
2. Materials and methods
2.1. Patients and study design
The Cardiovascular and Periodontal study (CAPS), conducted at the
Prince Charles Hospital (Brisbane, Australia), was a randomised, double
blind, placebo controlled, clinical trial over 5-years that compared the
effects of a toothpaste containing 0.3% triclosanwith placebo toothpaste
on the progression of periodontitis and the incidence of secondary car-
diovascular events in patients with coronary heart disease. The trial was
registered with the Australian New Zealand Clinical Trials Registry
ACTRN12605000593639. Inclusion criteria were a history of a cardio-
vascular event (hospital admission for myocardial infarction, unstable
angina or abnormal cardiograph) in the preceding three years, a mini-
mum of twelve uncrowned teeth (excluding third molars) and age up
to 75 years. Exclusion criteria were any other serious disease or require-
ment for antibiotic cover prior to dental procedures. CAPS commenced 8
November 2000 and was completed 3 November 2010. The study pro-
tocols were approved by the Research Ethics Committees of the Prince
Charles Hospital and the University of Queensland (EC9957, D/13/
Dent/00). Contact letters were sent to 4344 patients, of these, 174 let-
ters were returned to sender and 1246 patients indicated willingness
to join the study. Four hundred and thirty eight patientsmeeting the in-
clusion criteria and giving informed consent entered the trial. The pri-
mary outcome of CAPS was progression of periodontitis in terms of
probing pocket depth (PPD) and loss of attachment (LOA), therefore
the sample size calculation, based on the assumption that 10% of the
controls would have periodontitis progression over 5-years, and a 25%
dropout rate over 5-years, indicated that a sample size of 200 per
group (i.e. 150 per group at year-5) would have 80% certainty of detect-
ing a 20% difference between the test and control groups in periodontal
disease progression when testing at the 5% signiﬁcance level. As part of
this RCT adverse events were monitored. A power analysis indicates
that with a sample size of 215 placebo and 223 triclosan patients, a log
rank test would be 80% certain of detecting as signiﬁcant, at the 5%
level, a reduction of 28.5% in the median survival time of the triclosan
group compared with the placebo group.
2.2. Randomisation, allocation concealment
Randomisation utilised computer generated random sequences
prior to study commencement. Patients were allocated an identiﬁcation
number consecutively and assigned to allocated group by a dental assis-
tant. Group A received placebo toothpaste and Group B, toothpastewith
triclosan (0.3% [wt/wt]). Although the test toothpaste is commercially
available, all study personnel and participants were blinded to alloca-
tion as both toothpastes were packaged in identical white tubes. The
placebo toothpaste was identical to the test with the exception that it
did not contain the triclosan/co-polymer.Table 1
Baseline demographics.
Placebo
(n = 215)
Triclosan
(n = 223)
p-Values
Age, years (SD) 60.7 (8.5) 61.4 (8.6) 0.40⁎
Males, n (%) 170 (79) 172 (77) 0.62⁎⁎
BMI (SD) 28.2 (4.5) 28.9 (5.5) 0.17⁎
Smokers, n (%) 28 (13) 22 (10) 0.30⁎⁎
Statins, n (%)⁎⁎⁎ 192 (89.3) 189 (84.8) 0.16⁎⁎
Anti-inﬂammatories, n (%)⁎⁎⁎ 32 (14.9) 27 (12.1) 0.40⁎⁎
⁎ t-Test (independent samples).
⁎⁎ Chi square test.
⁎⁎⁎ At baseline.2.3. General health assessments
General health assessments were carried out at baseline and subse-
quently at each yearly appointment by a Registered Nurse and consisted
of a personalised interview, a general health questionnaire, measurement
of height,weight and bloodpressure plus blood collection. Followupwith
patients' own medical practitioner or hospital occurred when necessary.
The SAEs were deﬁned according to the European Commission's
Directorate-General for Enterprise and Industry: “Detailed guidance
on the collection, veriﬁcation and presentation of adverse reaction
reports arising from clinical trials on medicinal products for human
use” (April 2006) http://ec.europa.eu/health/ﬁles/eudralex/vol-10/21_
susar_rev2_2006_04_11_en.pdf.
SAEs were classiﬁed according to the System Organ Classes
deﬁned byMedDRA (Medical Dictionary for Regulatory Activities)version
9.0: http://www.hptn.org/web%20documents/AnnualMeeting2006/
TuesPresentations/MedDRAtrainingHuntley2_2006.pdf.
Participants received oral hygiene instruction at baseline only and
thereafter care with their general dental practitioner, if they had one.2.4. Statistical analysis
Statistical analyses were carried out using SPSS v22.0 (SPSS Inc., Chi-
cago, Illinois). Chi square tests were used to assess differences betweenTable 2b
Number of cardiovascular events in each patient group, and percentage of the total num-
ber of cardiovascular events in each group that fell into each of the classes.
Triclosan
(n (%) of events)
Placebo
(n (%) of events)
Cardiac events Unstable angina/MI 60 (58.3) 42 (47.2)
Arrhythmia 11 (10.7) 10 (11.2)
Other 15 (14.6) 13 (14.6)
Vascular events 17 (16.5) 24 (27.0)
Total 103 (100.0) 89 (100.0)
Table 3a
Number (%) experiencing ≥1 serious adverse event.
Placebo Triclosan Chi-sq p-value
All 109/215 (51%) 123/223 (55%) 0.35
Females 22/45 (49%) 23/51 (45%) 0.71
Males 87/170 (51%) 100/172 (58%) 0.20
≤60 yrs 50/110 (46%) 58/108 (54%) 0.22
N60 yrs 59/105 (56%) 65/115 (57%) 0.96
BMI ≤ 25 28/49 (57%) 29/50 (58%) 0.93
BMI N 25 81/166 (49%) 94/173 (54%) 0.31
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respect to the proportions of patients experiencing at least one serious
adverse event (SAE). As this population represents a susceptible group
for further cardiovascular events, similar tests were done for the pro-
portions experiencing at least one cardiovascular SAE.
Logistic regression was used to calculate both unadjusted and ad-
justed odds ratios for the occurrence of SAEs and cardiovascular SAEs
separately. In both analyses, toothpaste group and gender were includ-
ed as factors, along with baseline age and BMI values as covariates.
Time (in weeks) from baseline to the occurrence of the ﬁrst SAEwas
calculated for each subject. The Kaplan–Meier (K–M)method was used
to estimate the SAE-free survival rates, and K–M plots for SAE-free
survival were constructed for each of the treatment groups, both
overall and for sub-groups of gender, age (≤60/N60 years) and BMI
(≤25/N25 kg/m2). The divergence of the curves, in particular the cross-
ing of the curves, indicated non-proportional hazards (i.e. the ratio of
the survival probabilities for the two groups being compared is not
roughly constant over time), so survival times across the groups were
compared using the Tarone–Ware Test (Tarone and Ware, 1977)
which has been shown to have good power across a wide range of sur-
vival functions. Similar analyses were carried out for times to the occur-
rence of the ﬁrst cardiovascular SAE. For this analysis a Bonferroni
adjustment of the signiﬁcance level to 0.004, was made to allow for
the multiplicity of tests performed.3. Results
Of the 1246 patients who indicated willingness to be part of the
study, 438 met the inclusion criteria and entered the study (Fig. 1).Table 3b
Number (%) experiencing ≥1 serious cardiovascular event.
Placebo Triclosan Chi-sq p-value
All 56/215 (26%) 56/223 (25%) 0.82
Females 14/45 (31%) 8/51 (16%) 0.07
Males 42/170 (25%) 48/172 (28%) 0.50
≤60 yrs 24/110 (22%) 27/108 (25%) 0.58
N60 yrs 32/105 (30%) 29/115 (25%) 0.38
BMI ≤ 25 13/49 (27%) 8/50 (16%) 0.20
BMI N 25 43/166 (26%) 48/173 (28%) 0.70
Table 4a
Odds ratios for occurrence of ≥1 serious adverse event.
Factor/covariate Odds ratio (95% conf int)
Univariable models
Triclosan 1.196
(0.82, 1.74)
Male gender 1.367
(0.87, 2.15)
Age at baseline (yrs) 1.024
(1.00, 1.05)
BMI at baseline (kg/m2) 1.023
(0.99, 1.06)
⁎ Each factor/covariate has been adjusted for the other factors/covariates.The demographic data in Table 1 indicate that the triclosan and placebo
groups were very similar in age, gender, the proportions of current cig-
arette smokers and inmedication use. The over-representation of males
is typical of a cardiovascular disease population.
Overall, there were 569 SAEs recorded, 288 in the 223 triclosan pa-
tients and 281 in the 215 placebo patients (Table 2a). Of the 118 general
disorders and administration site conditions, all except one were chest
pain of unknown cause. Of the 151 cardiac disorders, 102were unstable
angina or myocardial infarcts and 21 were related to arrhythmia. The
other 28 cardiac disorders included heart failure (11), syncope (6) and
pericarditis (2). Themost common of the 41 vascular disorders were ce-
rebrovascular accidents (8) transient ischaemic attacks (7) and aortic
aneurysms (6) (Table 2b).
There were 232 patients (123 triclosan, 109 placebo) who experi-
enced at least one SAE, and of these, 105 (56 triclosan, 49 placebo) ex-
perienced only a single event. There were 112 patients (56 per group)
who experienced at least one cardiovascular SAE and of these, 66 (28
triclosan, 38 placebo) experienced only a single event. However, the
chi square analysis showed that there was no signiﬁcant difference be-
tween the groups in the proportions of patients experiencing SAEs
or cardiovascular SAEs, either overall or in any of the subgroups
(Tables 3a and 3b).
The logistic regression showed that the use of triclosan toothpaste,
male gender, older age and higher BMI values all had both unadjusted
and adjusted odds ratios (ORs) for SAEs greater than 1.0. Only age how-
ever, was signiﬁcantly associated with SAEs, this was more so after
adjusting for confounding by the other variables (Table 4a). The adjust-
ed odds of experiencing an SAE were estimated to increase by 2.7% for
each year of age (p = 0.02).
In terms of cardiovascular SAEs, the use of triclosan toothpaste had
both an unadjusted and adjusted OR less than 1.0, although neither
was signiﬁcant. At the same time, male gender, older age and higher
BMI values had ORs greater than 1.0 for cardiovascular SAEs. However,
only BMI was signiﬁcantly associated, especially after adjusting for con-
founding by the other variables (Table 4b). The adjusted odds of
experiencing a cardiovascular SAE were estimated to increase by 5.1%
for each unit increase in BMI (p = 0.02).
From the K–Mplots it can be seen that for the ﬁrst two years, surviv-
al rates for the two groups with regard to occurrence of ﬁrst SAE were
remarkably similar. For the next 2 years survival rates decreased more
rapidly for those using triclosan, but after that the decrease was more
rapid for the placebo group (Fig. 2).
For the ﬁrst 4-years (200 weeks), the survival rates with regard to
the occurrence of the ﬁrst cardiovascular SAE decreased somewhat
more rapidly for those using triclosan, but after that the decrease was
more rapid for those on the placebo (Fig. 3).
Both overall and for most of the subgroups considered, there were
no statistically signiﬁcant differences in the mean times to occurrence
of the ﬁrst SAE between the placebo group and for those using triclosan
(Table 5a). Although the study was not powered to detect an effect
when stratifying by gender, for males in the triclosan group there ap-
peared to be a shorter time to their ﬁrst SAE compared with those inp-Value Multivariable model⁎ p-Value
0.35 1.165
(0.80, 1.71)
0.43
0.18 1.417
(0.90, 2.24)
0.14
0.04 1.027
(1.00, 1.05)
0.02
0.24 1.029
(0.99, 1.07)
0.16
Table 4b
Odds ratios for occurrence of ≥1 cardiovascular serious adverse event.
Factor/covariate Odds ratio (95% conf int)
Univariable models p-Value Multivariable model⁎ p-Value
Triclosan 0.907
(0.59, 1.40)
0.66 0.863
(0.56, 1.34)
0.51
Male Gender 1.317
(0.76, 2.28)
0.33 1.358
(0.78, 2.37)
0.28
Age at baseline (yrs) 1.018
(0.99, 1.05)
0.18 1.024
(0.997, 1.05)
0.08
BMI at baseline (kg/m2) 1.042
(1.00, 1.09)
0.05 1.049
(1.005, 1.096)
0.03
⁎ Each factor/covariate has been adjusted for the other factors/covariates.
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ple comparisons, pN0.004). Equally, there was no difference between
the groups in the mean time to ﬁrst cardiovascular event (Table 5b).
4. Discussion
Overall, the results of the present study indicate that the long-term
use of a triclosan toothpaste over a 5-year period did not lead to an in-
crease in serious adverse events nor to an increase in secondary cardio-
vascular events in this susceptible population. The current study
extends our earlier ﬁndings of no untoward effects of triclosan on thy-
roid function in this population (Cullinan et al, 2012) to include all ad-
verse events and showed that there was no signiﬁcant difference
between the groups either in the numbers of patients experiencing
SAEs or in the time to the ﬁrst SAE, irrespective of gender or age. For
males in the triclosan group there appeared to be a shorter time to
their ﬁrst SAE compared with those in the placebo group. Although
this effect of triclosan was of marginal signiﬁcance it was one of many
possible effects investigated and the study did have low power to detect
such effects so this ﬁnding could, not unreasonably, be put down toBaseline 100 weeks 200 weeks 300 weeks
Placebo (n) 215 127 91 0
Triclosan (n) 223 121 74 2
Fig. 2. Kaplan–Meier survival curves illustrating time to occurrence of ﬁrst SAE for each of
the toothpaste groups (Triclosan versus placebo).chance variation. Indeed, a limitation of the present study was that it
was not speciﬁcally designed to have sufﬁcient power to detect an effect
when stratifying by gender. While there is no biological explanation for
this ﬁnding at present, follow up studies speciﬁcally designed with suf-
ﬁcient power are needed.
CAPS was a randomised controlled clinical trial aimed at determin-
ing the inﬂuence of triclosan toothpaste on the progression of periodon-
titis in patientswith cardiovascular disease over 5-years. All participants
in the study had a history of a cardiovascular event (hospital admission
for myocardial infarction, unstable angina or abnormal electrocardio-
graph) in the preceding 3-years and as such represented an at-risk
group for secondary cardiovascular events. In this context, there was
no signiﬁcant difference between the groups in terms of the numbers
of patients experiencing a serious cardiovascular event, nor was there
any signiﬁcant difference between the groups in time to ﬁrst serious
cardiovascular event. Most of the cardiovascular events were related
to unstable angina or myocardial infarcts, followed by arrhythmia and
vascular events such as aortic aneurysm and cerebrovascular accident.
Other conditions included heart failure and pericarditis. This is the
ﬁrst study to look speciﬁcally at the effect of long-term use of a triclosanBaseline 100 weeks 200 weeks 300 weeks
Placebo (n) 215 164 115 0
Triclosan (n) 223 157 114 3
Fig. 3. Kaplan–Meier survival curves illustrating time to occurrence of ﬁrst cardiovascular
SAE for each of the toothpaste groups (Triclosan versus placebo).
Table 5a
Mean and median times (weeks) to ﬁrst serious adverse event.
Placebo Triclosan
Mean
(s.e.)
Median
(s.e.)
Mean
(s.e.)
Median
(s.e.)
Tarone–Ware
p-Value
All 184 (8.0) 220 (18.0) 173 (8.7) 150 (17.9) 0.20
Females 166 (19.4) 119 ⁎⁎ 187 (16.1) 266 (34.1) 0.26
Males 187 (8.5) 223 (14.6) 167 (9.8) 139 (20.5) 0.04⁎
≤60 yrs 196 (10.2) 249 (13.0) 179 (12.4) 156 (26.8) 0.08
N60 yrs 168 (11.7) 182 (52.5) 159 (10.7) 142 (23.3) 0.95
BMI ≤ 25 171 (15.5) 220 (73.0) 170 (15.8) 151 (92.7) 0.72
BMI N 25 186 (9.1) 220 (21.2) 173 (10.0) 146 (19.4) 0.12
⁎ Not signiﬁcant after adjustment for multiple comparisons (p N 0.004).
⁎⁎ Survival function does not reach 0.45 (s.e. not calculable).
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the fact that this population represented an at-risk population for such
events, there was no difference between the triclosan and placebo
groups suggesting that the use of triclosan toothpaste does not increase
the risk of cardiovascular events.
While a number of animal studies have suggested the possibility of
serious systemic effects following ingestion of triclosan (Crofton et al.,
2007; Paul et al., 2010), these studies incorportated much higher con-
centrations of triclosan (100–1000 mg/kg per day) than those that are
likely to occur normally in humans following toothpaste use. Rodricks
et al. (2010) estimated that twice-daily use of a 2 cm stripe of
toothpaste with 0.3% (w/w) triclosan would result in a concentration
of 1.9 g/day being ingested. This would be at the upper limit of that ex-
pected and certainly was more than in the present study, where a pea
sized amount (approximately 1 cm) twice daily was recommended. A
limitation of the current study however, was that actual concentrations
of triclosan in serumwere notmeasured and that nodatawere collected
on the use of other consumer products containing triclosan. Urinary tri-
closan concentrations show variability across age groups with a slight
decline with increasing age (Calafat et al., 2008). While the reason for
this declinewith age is unknown, Allmyr et al. (2008) previously report-
ed that in the Australian population, serum triclosan concentrations
from all sources varied from 6–10 ng/g in adults 46–60 years and from
6.2–8.7 ng/g for those over 60 years and that on average males from
the northeast of Australia had the highest triclosan levels. They further
showed that the Australian population had concentrations twice that
of a Swedish population, which was thought to reﬂect differences be-
tween the two countries in the use of personal care products containing
triclosan (Allmyr et al., 2006a, 2008).While it is possible that the higher
triclosan concentrations reported for the Australian population were
present in the current study population, no differences in terms of
SAEs between the groups were observed, suggesting that the use of
the toothpaste did not lead to an increased likelihood of a serious ad-
verse event. Due to the lack of data on the use of other triclosan prod-
ucts, however, it was not possible to determine any inﬂuence these
may have had on individual variation in both groups.
Another limitation of the present study is that only patients meeting
the inclusion criteria of having deﬁned cardiovascular disease were in-
cluded. As a result, the patients were predominantly older males taking
an array of medications and therefore may not reﬂect the generalTable 5b
Mean times (weeks) to ﬁrst serious cardiovascular event.
Placebo
Mean (s.e.)
Triclosan
Mean (s.e.)
Tarone–Ware
p-Value
All 242 (6.5) 260 (8.5) 0.71
Females 220 (17.0) 248 (12.9) 0.11
Males 248 (6.8) 252 (9.9) 0.19
≤60 yrs 249 (8.7) 252 (11.2) 0.41
N60 yrs 233 (9.5) 257 (12.1) 0.78
BMI ≤ 25 233 (11.7) 243 (10.5) 0.22
BMI N 25 241 (7.5) 251 (10.0) 0.31population as a whole. In addition, because of the nature of this popula-
tion it was not possible to study the occurrence of hormone-related dis-
ease, such as breast cancer and in this context, as yet, there are
insufﬁcient studies in humans to determine the long-term impact of tri-
closan on hormone-related diseases. Nevertheless, this group was con-
sidered to be a particularly susceptible population for a wide range of
serious adverse events and as such was ideally suited to detect any in-
crease in adverse effects due to the use of the triclosan toothpaste.
In conclusion, and within the limitations of the current study, the
data suggest that continuous use of triclosan-toothpaste over 5 years
had no detectable effect on the occurrence of SAEs or in particular car-
diovascular SAEs, in this population.
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